Reveromycin A – 250 µg

Brand:
Cayman
CAS:
134615-37-5
Storage:
-20
UN-No:
Non-Hazardous - /

Reveromycin A is the major component of a complex of spiroketal antibiotics isolated from Streptomyces sp. It inhibits the mitogenic activity of epidermal growth factor in Balb/MK cells (IC50 = 0.7 µg/ml), displays antiproliferative activity against human KB and K562 tumor cell lines (IC50s = 1.9 and 1.6 µg/ml, respectively), and demonstrates antifungal activity against C. albicans (MIC = 2 µg/ml at pH 3).{28254} Reveromycin A also has been shown to inhibit bone resorption by inducing apoptosis in osteoclasts with an IC50 value of 0.7 µM.{28255}  

 

Available on backorder

SKU: - Category:

Description

A spiroketal antibiotic that inhibits EGF mitogenic activity, displays antiproliferative activity against human tumor cells, and demonstrates antifungal activity; inhibits bone resorption by inducing apoptosis in osteoclasts with an IC50 value of 0.7 µM


Formal name: butanedioic acid, 1-[(2S,3R,6S,8R,9S)-3-butyl-8-[(2E,4E,6S,7S,8E)-9-carboxy-6-hydroxy-3,7-dimethyl-2,4,8-nonatrien-1-yl]-2-[(1E,3E)-4-carboxy-3-methyl-1,3-butadien-1-yl]-9-methyl-1,7-dioxaspiro[5.5]undec-3-yl] ester

Synonyms: 

Molecular weight: 660.8

CAS: 134615-37-5

Purity: ≥99%

Formulation: A lyophilisate


Product Type|Biochemicals|Antifungals||Product Type|Biochemicals|Natural Products|Microbial Metabolites||Research Area|Cancer||Research Area|Endocrinology & Metabolism|Bone Growth & Remodeling||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Fungal Diseases|Candidiasis